Adamax

A pegylated Semax analog sold by grey-market nootropic vendors as a "stronger, longer-lasting Semax". Unlike Semax itself, it has essentially no published record anywhere — it is a vendor invention built on a real molecule's reputation.

Adamax is a synthetic peptide sold in the research-chemical market, described as an adamantane-modified analogue related to the Russian nootropic peptide family — the same lineage as semax and selank. The adamantane group is a structural modification used elsewhere in pharmacology to improve stability and brain penetration. The proposed effects follow the family template: neurotrophic signalling, BDNF, cognitive enhancement. What separates it from semax and selank is that those at least have an approved status and a clinical literature somewhere; this has neither.

None. Not thin — none: no trials, no animal literature under this name, nothing to audit. Everything claimed for it is extrapolated from Semax plus the assumption that pegylation only changes duration. That assumption is doing all the work.

• NONE. There is no human trial, no approved status in any country, and no published clinical literature of any kind.
• It is not a Russian pharmaceutical with an unreplicated literature — it is a research-chemical-market compound whose claims are extrapolated from the peptide family it resembles.
• The BDNF and neurotrophic claims attached to it derive from work on OTHER peptides in that family, and even those findings are largely preclinical or unreplicated.
• For a nasally administered peptide, the practical risks are impurity, endotoxin and sterility of the product rather than any characterised pharmacology — and none of those is verifiable for research-chemical supply.
• Because it is obscure, it lacks even the user-report base that more popular compounds accumulate.

Human pharmacokinetics do not exist. No bioavailability, half-life or clearance figure has been established for people, and any number in circulation is invention or extrapolation from unrelated peptides. Typically sold as a nasal preparation or powder for reconstitution.

The unknowns of Semax multiplied by a modification nobody has studied, from a supply chain with no pharmacopeia standard. Intranasal self-administration of an uncharacterized peptide is the entire risk profile: nobody can tell you what it does because nobody has looked.

• Everyone — no human data, no approved status anywhere, and claims borrowed from other compounds
• Anyone pregnant or breastfeeding
• Anyone taking prescribed medication, where the interaction cannot be checked
• Anyone administering an unverified peptide nasally, where sterility and endotoxin cannot be assessed

• Unknown. No interaction profile exists for a compound with no human study.
• The practical risk is with prescribed medication, where neither you nor a prescriber can look up what an uncharacterised peptide does.

• There is no monitoring that means anything for a compound nobody has studied.
• For nasal peptide products the concrete concerns are local irritation and, more seriously, what is actually in the vial — impurity and endotoxin risk cannot be assessed by the buyer.
• Tell a clinician what you have taken by its actual name if anything goes wrong; "a nootropic peptide" is not workable information.

Nothing can be said about stopping a compound nobody has studied. No withdrawal syndrome is described and no established effect exists to lose.

US: not approved, not scheduled — pure grey-market "research chemical".